Bionomics Limited Price (BNO.AX)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

9,986,702

(99.32)%

Bionomics Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $0.009-0.074
  • Market Cap 13.22M
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Dr. Spyridon Papapetropoulos M.D., Ph.D.
  • IPO Date: December, 20, 1999
  • Country: AU
  • Currency: AUD
  • Headquaters: Eastwood, SA
  • Employees: 140

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation